Protein Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Protein Sequencing Market is projected to expand from USD 1.69 Billion in 2025 to USD 2.75 Billion by 2031, reflecting a compound annual growth rate of 8.45%. This process, which entails identifying the exact amino acid sequence within a protein to decipher its function and structure, is seeing increased demand due to the growing importance of proteomics in drug development and personalized medicine. The rise in chronic disease prevalence acts as a further catalyst, creating a need for new biomarkers to aid in early detection and treatment monitoring. For instance, the American Cancer Society estimates that the United States will surpass 2 million new cancer cases in 2024, highlighting the urgent necessity for sophisticated proteomic profiling within oncology.

However, the industry encounters substantial obstacles related to the expense and technical intricacy of sequencing tools. Because proteins cannot be amplified like genomic DNA, high-sensitivity and costly equipment are required to accurately identify low-abundance molecules. This heavy financial requirement, coupled with a worldwide shortage of qualified bioinformaticians who can analyze the resulting complex data, limits the technology's adoption in smaller labs and hinders its ability to scale rapidly.

Market Drivers

Increasing investments from both public and private sectors in proteomics research function as a major market stimulant, facilitating the movement of sensitive sequencing platforms from the prototype stage to commercial availability. This surge in funding enables newer biotechnology companies to surmount the steep financial barriers linked to equipment costs and to expand their production capacities. For example, a press release from Alamar Biosciences in February 2024 titled 'Alamar Biosciences Closes $128 Million Series C Financing' noted that the firm obtained significant funds to speed up the release of its automated proteomics system, demonstrating robust investor faith in advanced protein analysis. This financial strength also supports market consolidation, allowing firms to maintain operations despite high costs; as per Standard BioTools Inc.'s January 2024 press release 'Standard BioTools Completes Merger with SomaLogic', the merged organization announced pro forma full-year 2023 revenue of roughly $180 million, indicating significant economic scale in the industry.

Additionally, the incorporation of bioinformatics and artificial intelligence into proteomic workflows acts as a crucial driver by resolving data interpretation bottlenecks associated with complex sequencing. AI algorithms are proving essential for rapid and precise de novo sequencing and the detection of post-translational modifications, processes that formerly demanded extensive manual effort.

These technological improvements are reshaping pharmaceutical approaches, resulting in significant partnerships focused on AI-based discovery. As announced in January 2024 by Eli Lilly and Company in 'Lilly enters into strategic collaboration with Isomorphic Labs', the company committed to a $45 million upfront payment to utilize AI for multi-target drug discovery, marking a substantial pivot towards computational methods in proteomics. By automating complex data analysis, these innovations lessen reliance on scarce bioinformatics experts and accelerate the progression from sequencing to therapeutic target confirmation.

Market Challenges

The Global Protein Sequencing Market faces a major obstacle due to the exorbitant cost and technical intricacy of sequencing instruments. Because proteins do not support amplification like genomic materials, effective detection of low-abundance molecules requires highly sensitive and expensive equipment. This necessity drives up the price of machinery, establishing a formidable barrier for numerous prospective users. As a result, the deployment of these advanced technologies is frequently restricted to well-funded institutions, effectively locking out smaller research labs that cannot sustain such heavy capital expenditures.

This financial barrier is especially detrimental considering the structure of the broader industry. Data from MedTech Europe in 2024 indicates that small to medium-sized enterprises make up roughly 90% of the medical technology sector. Given that these smaller entities with tighter budgets dominate the market, the prohibitive cost of instrumentation directly hampers the widespread adoption and scalability of protein sequencing. Moreover, the shortage of qualified bioinformaticians skilled in analyzing the intricate data produced forms an operational choke point, further deterring smaller laboratories that lack the means to recruit such specialized staff.

Market Trends

The industry is being transformed by a transition toward semiconductor-based sequencing chips, which facilitate single-molecule protein detection without requiring amplification or intricate optical setups. This technological advancement enables amino acid sequences to be read directly on solid-state devices, drastically lowering the cost and physical size of analysis tools while improving sensitivity for proteins present in low quantities. The commercial feasibility of this method is gaining clarity as early users incorporate these platforms into their regular processes to overcome the constraints of conventional bulk techniques. For instance, Quantum-Si's press release from March 2025, 'Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results', noted a 183% year-over-year revenue jump to $3.1 million, highlighting the surging demand for these semiconductor-driven proteomic technologies.

Concurrently, the merging of protein sequencing with multiomics research is redefining experimental approaches, as researchers aim to link genomic information with phenotypic proteomic outputs. This movement fosters the creation of unified workflows that permit the analysis of both proteins and DNA on a population level, offering a more complete picture of disease processes. Major biobanking projects are leading this charge, building extensive biological datasets to aid high-throughput drug development and biomarker confirmation. As an example, Illumina, Inc. announced in a January 2025 press release titled 'Illumina launches pilot proteomics program with UK Biobank and biopharma collaborators to analyze 50,000 samples' that it has begun a project to produce next-generation sequencing-based proteomics data for 50,000 subjects, demonstrating the vast scale of current multiomics integration efforts.

Key Players Profiled in the Protein Sequencing Market

• Thermo Fisher Scientific Inc.
• Shimadzu Corporation
• Agilent Technologies, Inc.
• Rapid Novor, Inc.
• Charles River Laboratories
• Proteome Factory AG
• Selvita
• Bioinformatics Solutions Inc.
• Creative Proteomics
• Alphalyse

Report Scope

In this report, the Global Protein Sequencing Market has been segmented into the following categories:

Protein Sequencing Market, by Product & Service:

• Protein Sequencing Products
• Reagents & Consumables
• Instruments
• Software
• Protein Sequencing Services

Protein Sequencing Market, by Application:

• Bio-therapeutics
• Genetic Engineering
• Others

Protein Sequencing Market, by End Use:

• Academic Institutes & Research Centers
• Pharmaceutical & Biotechnology
• Others

Protein Sequencing Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Protein Sequencing Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.